

Cases from the Community: Investigators Discuss the Optimal Management of EGFR-Mutated Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate objective response rate observed with Dato-DXd for patients with previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC) in a combined analysis of the TROPION-Lung01 and TROPION-Lung05 studies?
 - a. 14%
 - b. 28%
 - c. 43%
 - d. 70%
2. Which of the following outcomes best describes results with subcutaneous amivantamab in comparison to historical IV administration, both with oral lazertinib, for patients with pretreated EGFR-mutated advanced NSCLC in the Phase III PALOMA-3 trial?
 - a. Decreased overall survival (OS) but improved safety profile
 - b. Similar OS and improved safety profile
 - c. Increased OS and improved safety profile
 - d. Increased OS but slightly worse safety profile
3. In the Phase III MARIPOSA trial, how did the incidence of acquired EGFR resistance mutations compare between patients who received first-line amivantamab/lazertinib and those who received osimertinib?
 - a. Incidence was generally similar
 - b. Incidence was increased approximately twofold with amivantamab/lazertinib
 - c. Incidence was increased approximately fivefold with amivantamab/lazertinib
 - d. Incidence was decreased approximately twofold with amivantamab/lazertinib
 - e. Incidence was decreased approximately fivefold with amivantamab/lazertinib
4. Which of the following outcomes best describes interim results of the Phase II COCOON trial for patients receiving first-line amivantamab/lazertinib for advanced EGFR-mutated NSCLC?
 - a. Significant reduction in the incidence and severity of infusion-related reactions
 - b. Significant reduction in the frequency of moderate to severe skin and nail side effects
 - c. Significant reduction in the risk of keratitis and other ocular toxicities
 - d. Significant reduction in the rate of discontinuation due to interstitial lung disease/pneumonitis
5. In an analysis of the TROPION-Lung01 study, Dato-DXd demonstrated a CNS objective response rate of approximately _____ for patients with previously treated metastatic NSCLC.
 - a. 5%
 - b. 15%
 - c. 38%
 - d. 60%